IP Library › Granted Patent US 9,655,988
Granted Patent B2
US 9,655,988 · App. 14/693,854 · Granted May 23, 2017

Gelatin-transglutaminase hemostatic dressings and sealants

Inventors: Natalie Iram (Tel Aviv-Yafo, IL); Orahn Preiss-Bloom (Zichron Yakov, IL); Ishay Attar (Haifa, IL)
Assignee: LIFEBOND LTD
A61L15/38A61L15/32A61L15/325A61L15/42A61L15/585A61L24/043A61L24/104A61L26/0038A61L26/0047A61L26/0052A61L26/0061A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,988
App. No.
14/693,854
Granted
May 23, 2017
Kind
B2
Abstract

An adhesive material for medical use comprising gelatin and a non-toxic cross-linking material such as transglutaminase. An optional embodiment of the invention includes dressings in which a layer of a transglutaminase is sandwiched between a first and second layer of gelatin. The hemostatic products are useful for the treatment of wounded tissue.

Claims (17)

1. A method of creating a barrier to fluid leakage or bleeding in a subject, comprising applying a sealing agent to a tissue of the subject, wherein said agent comprises a composition of gelatin and a transglutaminase in an amount sufficient to induce fluid sealing; wherein said transglutaminase has a specific gelatin crosslinking activity of from 40 U to 200 U/gm of gelatin and in which a weight ratio of gelatin to transglutaminase is in a range of from 1:1 to 300:1.

2. The method of claim 1 , further comprising inducing cross-linking between gelatin chains and endogenous collagen of tissue extracellular matrix to create the fluid barrier.

3. The method of claim 1 , wherein said transglutaminase comprises a plant, recombinant, animal, or microbe derived transglutaminase other than blood derived Factor XIII.

4. The method of claim 3 , wherein said animal origin is selected from the group consisting of fish and mammals.

5. The method of claim 3 , wherein said microbial derived transglutaminase is isolated from one or more of Streptoverticillium aldaccii, Streptomyces hygroscopicus , or Escherichia coli.

6. The method of claim 1 , wherein said agent has a pH in a range of from 5 to 8.

7. The method of claim 1 , wherein said agent further comprises a stabilizer or a filler.

8. The method of claim 1 , wherein gelatin is purified to remove salts.

9. The method of claim 8 , wherein said transglutaminase comprises a recombinant transglutaminase.

10. The method of claim 1 , wherein said agent induces hemostasis or stasis of leaking bodily fluids in or from said tissue.

11. The method of claim 1 , wherein bodily fluid is selected from the group consisting of blood, cerebral spinal fluid, intestinal fluid, air, bile, and urine.

12. The method of claim 1 , wherein said agent induces the formation of a biomimetic clot at a site of a damaged blood vessel.

13. The method of claim 12 , wherein said blood vessel is an artery.

14. The method of claim 1 , wherein said tissue is a wound site and wherein said wound site is selected from the group consisting of surgically cut tissue and traumatized tissue.

15. The method of claim 14 , wherein said wound site is located in an organ selected from the group consisting of skin, muscle, liver, stomach, kidneys, heart, lung and a combination thereof.

16. A method of creating a barrier to fluid leakage or bleeding in a subject, comprising applying a fluid sealing agent to a tissue of the subject, wherein said agent comprises a composition of gelatin and a transglutaminase, wherein said transglutaminase has a specific gelatin crosslinking activity of from 40 U to 200 U/gm of gelatin and in which a weight ratio of gelatin to transglutaminase is in a range of from 1:1 to 300:1.

17. The method of claim 16 , wherein said applying said fluid sealing agent to said tissue comprises cross linking between gelatin chains and endogenous collagen of tissue extracellular matrix by said transglutaminase to create said barrier to fluid leakage or bleeding.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: LIFEBOND LTD.
To: BARD SHANNON LIMITED
Reel/Frame 053230/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2020
From: PREISS-BLOOM, ORAHN; IRAM, NATALIE
To: LIFEBOND LTD.
Reel/Frame 052051/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2020
From: ATTAR, ISHAY
To: LIFEBOND LTD.
Reel/Frame 052051/0873 →
Continuity (4)
Continuation 12519167
Provisional Application 61000887 · Oct 30, 2007
Provisional Application 60875150 · Dec 15, 2006
Related Publication 20150273103A1 · Oct 1, 2015